These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 32903870)
1. Comparison of the Diagnostic Performance of C26:0-Lysophosphatidylcholine and Very Long-Chain Fatty Acids Analysis for Peroxisomal Disorders. Jaspers YRJ; Ferdinandusse S; Dijkstra IME; Barendsen RW; van Lenthe H; Kulik W; Engelen M; Goorden SMI; Vaz FM; Kemp S Front Cell Dev Biol; 2020; 8():690. PubMed ID: 32903870 [TBL] [Abstract][Full Text] [Related]
2. Plasma C24:0- and C26:0-lysophosphatidylcholines are reliable biomarkers for the diagnosis of peroxisomal β-oxidation disorders. Morales-Romero B; González de Aledo-Castillo JM; Fernández Sierra C; Martínez Carreira C; Zaragoza Bonet C; Fernández Bonifacio R; Caro Miró MA; Argudo-Ramírez A; López Galera RM; García-Villoria J J Lipid Res; 2024 Mar; 65(3):100516. PubMed ID: 38320654 [TBL] [Abstract][Full Text] [Related]
3. A pilot study of newborn screening for X-linked adrenoleukodystrophy based on liquid chromatography-tandem mass spectrometry method for detection of C26:0-lysophosphatidylcholine in dried blood spots: Results from 43,653 newborns in a southern Chinese population. Tang C; Tang F; Cai Y; Tan M; Liu S; Xie T; Jiang X; Huang Y Clin Chim Acta; 2024 Jan; 552():117653. PubMed ID: 37977233 [TBL] [Abstract][Full Text] [Related]
4. Improved analysis of C26:0-lysophosphatidylcholine in dried-blood spots via negative ion mode HPLC-ESI-MS/MS for X-linked adrenoleukodystrophy newborn screening. Haynes CA; De Jesús VR Clin Chim Acta; 2012 Aug; 413(15-16):1217-21. PubMed ID: 22503909 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of C26:0-lysophosphatidylcholine and C26:0-carnitine as diagnostic markers for Zellweger spectrum disorders. Klouwer FCC; Ferdinandusse S; van Lenthe H; Kulik W; Wanders RJA; Poll-The BT; Waterham HR; Vaz FM J Inherit Metab Dis; 2017 Nov; 40(6):875-881. PubMed ID: 28677031 [TBL] [Abstract][Full Text] [Related]
6. High incidence of null variants identified from newborn screening of X-linked adrenoleukodystrophy in Taiwan. Chen HA; Hsu RH; Chen PW; Lee NC; Chiu PC; Hwu WL; Chien YH Mol Genet Metab Rep; 2022 Sep; 32():100902. PubMed ID: 36046390 [TBL] [Abstract][Full Text] [Related]
7. Streamlined determination of lysophosphatidylcholines in dried blood spots for newborn screening of X-linked adrenoleukodystrophy. Turgeon CT; Moser AB; Mørkrid L; Magera MJ; Gavrilov DK; Oglesbee D; Raymond K; Rinaldo P; Matern D; Tortorelli S Mol Genet Metab; 2015 Jan; 114(1):46-50. PubMed ID: 25481105 [TBL] [Abstract][Full Text] [Related]
8. Very long chain acylcarnitines and lysophosphatidylcholines in screening of peroxisomal disease in children by tandem mass spectrometry. Wang Y; Tian G; Ji W; Wang S; Zhang X Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 50(4):481-486. PubMed ID: 34704420 [TBL] [Abstract][Full Text] [Related]
9. Comparison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy. Huffnagel IC; van de Beek MC; Showers AL; Orsini JJ; Klouwer FCC; Dijkstra IME; Schielen PC; van Lenthe H; Wanders RJA; Vaz FM; Morrissey MA; Engelen M; Kemp S Mol Genet Metab; 2017 Dec; 122(4):209-215. PubMed ID: 29089175 [TBL] [Abstract][Full Text] [Related]
10. Liquid chromatography-tandem mass spectrometry method for estimation of a panel of lysophosphatidylcholines in dried blood spots for screening of X-linked adrenoleukodystrophy. Natarajan A; Christopher R; Netravathi M; Bhat M; Chandra SR Clin Chim Acta; 2018 Oct; 485():305-310. PubMed ID: 30018013 [TBL] [Abstract][Full Text] [Related]
11. Utility of measuring very long-chain fatty-acyl carnitines in dried blood spots for newborn screening of X-linked Adrenoleukodystrophy. Natarajan A; Christopher R; Palakuzhiyil SV; Chandra SR Mol Genet Metab Rep; 2021 Mar; 26():100720. PubMed ID: 33552912 [TBL] [Abstract][Full Text] [Related]
12. Sex-specific newborn screening for X-linked adrenoleukodystrophy. Albersen M; van der Beek SL; Dijkstra IME; Alders M; Barendsen RW; Bliek J; Boelen A; Ebberink MS; Ferdinandusse S; Goorden SMI; Heijboer AC; Jansen M; Jaspers YRJ; Metgod I; Salomons GS; Vaz FM; Verschoof-Puite RK; Visser WF; Dekkers E; Engelen M; Kemp S J Inherit Metab Dis; 2023 Jan; 46(1):116-128. PubMed ID: 36256460 [TBL] [Abstract][Full Text] [Related]
13. Flow injection ionization-tandem mass spectrometry-based estimation of a panel of lysophosphatidylcholines in dried blood spots for screening of X-linked adrenoleukodystrophy. Natarajan A; Christopher R; Netravathi M; Bhat MD; Chandra SR Clin Chim Acta; 2019 Aug; 495():167-173. PubMed ID: 30980791 [TBL] [Abstract][Full Text] [Related]
14. Newborn Screening for X-Linked Adrenoleukodystrophy (X-ALD): Biochemical, Molecular, and Clinical Characteristics of Other Genetic Conditions. Mares Beltran CF; Tise CG; Barrick R; Niehaus AD; Sponberg R; Chang R; Enns GM; Abdenur JE Genes (Basel); 2024 Jun; 15(7):. PubMed ID: 39062617 [TBL] [Abstract][Full Text] [Related]
15. Chinese patients with adrenoleukodystrophy and Zellweger spectrum disorder presenting with hereditary spastic paraplegia. Chen YJ; Wang MW; Dong EL; Lin XH; Wang N; Zhang ZQ; Lin X; Chen WJ Parkinsonism Relat Disord; 2019 Aug; 65():256-260. PubMed ID: 31227335 [TBL] [Abstract][Full Text] [Related]
16. Impaired very long-chain acyl-CoA β-oxidation in human X-linked adrenoleukodystrophy fibroblasts is a direct consequence of ABCD1 transporter dysfunction. Wiesinger C; Kunze M; Regelsberger G; Forss-Petter S; Berger J J Biol Chem; 2013 Jun; 288(26):19269-79. PubMed ID: 23671276 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of a panel of very long-chain lysophosphatidylcholines and acylcarnitines for screening of X-linked adrenoleukodystrophy in China. Tian GL; Xu F; Jiang K; Wang YM; Ji W; Zhuang YP Clin Chim Acta; 2020 Apr; 503():157-162. PubMed ID: 31978407 [TBL] [Abstract][Full Text] [Related]
18. Defining diagnostic cutoffs in neurological patients for serum very long chain fatty acids (VLCFA) in genetically confirmed X-Adrenoleukodystrophy. Rattay TW; Rautenberg M; Söhn AS; Hengel H; Traschütz A; Röben B; Hayer SN; Schüle R; Wiethoff S; Zeltner L; Haack TB; Cegan A; Schöls L; Schleicher E; Peter A Sci Rep; 2020 Sep; 10(1):15093. PubMed ID: 32934269 [TBL] [Abstract][Full Text] [Related]
19. Profiles of very-long-chain fatty acids in plasma, fibroblasts, and blood cells in Zellweger syndrome, X-linked adrenoleukodystrophy, and rhizomelic chondrodysplasia punctata. Schutgens RB; Bouman IW; Nijenhuis AA; Wanders RJ; Frumau ME Clin Chem; 1993 Aug; 39(8):1632-7. PubMed ID: 8353949 [TBL] [Abstract][Full Text] [Related]
20. The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy. Ofman R; Dijkstra IM; van Roermund CW; Burger N; Turkenburg M; van Cruchten A; van Engen CE; Wanders RJ; Kemp S EMBO Mol Med; 2010 Mar; 2(3):90-7. PubMed ID: 20166112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]